Navigation For Mobile

Archives

The Growing Impact of Rare Disease Drugs

AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals  joined by Merck’s acquisition of Acceleron for $11.5 billion and other deals, have made the Rare Disease space a destination for Big Pharma this…

Posted in drug discovery, drugs, FDA, Orphan drug | Tagged , | Comments Off on The Growing Impact of Rare Disease Drugs

Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

“Blockbuster” drugs — typically defined as those that generate annual sales of $1 billion or more — have been the lifeblood of Big Pharma company revenues since Smith, Kline and French’s…

Posted in blockbuster, drugs | Tagged , , , | Comments Off on Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

The Unblockbuster – Speeding Cures with Specialty Drugs

For years, industry soothsayers have suggested the imminent demise of blockbuster drugs was upon us (here’s one from 2009 – Goodbye blockbuster medicines; hello new pharmaceutical business models). But two…

Posted in blockbuster, CRO/CMO, drugs, generic, Orphan drug | Tagged , , , | Comments Off on The Unblockbuster – Speeding Cures with Specialty Drugs